Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;38(3):168-172.
doi: 10.1159/000522376. Epub 2022 Mar 1.

Today's Mistakes and Tomorrow's Wisdom… In Barrett's Surveillance

Pauline A Zellenrath  1 , Carlijn A M Roumans  1   2 , Manon C W Spaander  1
Affiliations
Review

Today's Mistakes and Tomorrow's Wisdom… In Barrett's Surveillance

Pauline A Zellenrath et al. Visc Med. 2022 Jun.

Abstract

Background: Barrett's esophagus (BE) is the only known precursor lesion of esophageal adenocarcinoma, a malignancy with increasing incidence and poor survival rates. To reduce mortality, regular endoscopic surveillance of BE patients is recommended to detect neoplasia in an (endoscopically) curable stage. In this review, we aim to provide an overview of current BE surveillance strategies, its pitfalls, and potential future directions to optimize BE surveillance.

Summary: Several societal guidelines provide surveillance strategies. However, when practicing those endoscopies multiple drawbacks are encountered. Important challenges are time-consuming biopsy protocols with low adherence rates, biopsy sampling error, interobserver variability in endoscopic detection of lesions, and interobserver variability in diagnosis of dysplasia. Furthermore, the overall efficacy and cost-effectiveness of surveillance are questioned. Using novel techniques, such as artificial intelligence and personalized surveillance intervals, can help to overcome these obstacles.

Key messages: Currently, there is room for improvement in BE surveillance. Better risk-stratification is expected to reduce both patient and healthcare burdens. Personalized and dynamic surveillance intervals accompanied by novel techniques in detection and histopathological assessment of dysplasia may be tools for a change in the right direction.

Keywords: Barrett's esophagus; Cost-effectiveness; Dysplasia; Risk-stratification; Surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Barrett's esophagus surveillance: its current pitfalls and potential future directions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19((34)):5598–606. - PMC - PubMed
    1. Fan J, Liu Z, Mao X, Tong X, Zhang T, Suo C, et al. Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017. Cancer Med. 2020;9((18)):6875–87. - PMC - PubMed
    1. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014;371((9)):836–45. - PubMed
    1. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96((5 Pt 1)):1249–56. - PubMed
    1. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168((3)):237–49. - PubMed